Brinzolamide
FDA Approved: * November 27, 2020Pharm Company: * WATSON LABS INC
Category: Vision / Eye Health
Brinzolamide (trade names Azopt, Alcon Laboratories, Befardin,[2] Fardi Medicals,[3] ) is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Brinzolamide was approved as a generic medication in the United States in November 2020.[4] Contents 1 Chemistry 2 Indications 3 Pharmacodynamics 4 Pharmacokinetics 4.1 Absorption 4.2 Distribution 4.3 Metabolism 4.4 Excretion 5... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.